CYTK Cytokinetics, Incorporated - Common Stock
$76,68
Fiyat · Ağu 19, 2026
Temel veriler itibarıyla Ağu 6, 2026
52 Haftlık Aralık
$35–$88
78% of range
Analist Derecelendirmesi
BUY
28 analysts
Fiyat Hedefi
$110
+43% upside
P/E (TTM)
-11.7
ROE
152.7%
Net Kâr Marjı
-891.6%
Cytokinetics, Incorporated - Common Stock Hakkında Wikipedia'dan şirket genel bakışı
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
Devamını oku
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
History
Cytokinetics was founded in 1997 by James Spudich, Ronald Vale, James Sabry and Lawrence S.B. Goldstein, four scientists at Stanford, UCSD, and UCSF. Operations began in 1998.
Initially, Cytokinetics focused on the possible pharmacological targets and areas of application of drugs based on cytoskeletal proteins. Eventually, the company narrowed its focus to the mechanics of muscle biology. Cytokinetics develops muscle activators and muscle inhibitors to improve muscle function in patients with cardiovascular and neuromuscular diseases.
In 2004 the company completed its initial public offering (IPO).
In January 2007, Cytokinetics named Robert I. Blum as president and CEO. Prior to this, Blum has been involved in the company since its founding, with roles in business development, corporate development and R&D.
In 2013, Cytokinetics finalized a licensing and discovery deal with Astellas to research treatment for muscle weakness and fatigue.
In July 2020, Ji Xing Pharmaceuticals signed a financing deal with Cytokinetics, which included the rights to commercialize the drug designed to treat hypertrophic cardiomyopathies, aficamten, in China and certain neighboring regions.
Products
Omecamtiv mecarbil is a cardiac muscle activator for the potential treatment of heart failure. In May 2020, omecamtiv mecarbil was granted fast track designation by the FDA for the treatment of chronic HF with reduced ejection fraction. Amgen purchased an option on omecamtiv mecarbil in 2006, and the two companies extended their partnership several times. In June 2013, Cytokinetics and Amgen expanded their licensing deal for omecamtiv mecarbil to include Japan. In November 2020 Amgen elected to terminate the collaboration, effective May 20, 2021, and Cytokinetics regained worldwide rights to develop and commercialize omecamtiv mecarbil.
Reldesemtiv (previously known as CK-2127107) is a next-generation fast skeletal muscle troponin activator (FSTA) that has undergone clinical trials for ALS.
Aficamten (previously known as CK-3773274) is an oral, small-molecule myosin inhibitor, to treat hypertrophic cardiomyopathy (HCM).
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
CYTK Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$76.67
Piyasa Değeri
$9.43B
P/E (TTM)
-11.7
EPS (TTM)
$-6.54
Gelir (TTM)
$88M
Temettü Verimi
—
ROE
152.7%
D/E Borç/Özsermaye
-0.4
52 Haftlık Aralık
$35 – $88
CYTK Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
Configure
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir ve Net Gelir
$88M
2016-12-31
→
2025-12-31
Hisse Başına Kâr
$-6.54
2016-12-31
→
2025-12-31
Serbest Nakit Akışı
$-535M
2016-12-31
→
2025-12-31
Marjlar
-891.6%
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
Metrik
5 Yıllık trend
CYTK
Akran Ortalaması
P/E (TTM)
-11.7
28.5
P/S (TTM) (F/S (TTM))
107.1
20.1
P/B (F/D)
-14.3
12.9
EV / EBITDA
-15.9
—
Price / FCF (Fiyat / Serbest Nakit Akışı)
-17.6
—
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
Metrik
5 Yıllık trend
CYTK
Akran Ortalaması
Operating Margin (Faaliyet Kâr Marjı)
-695.4%
—
Net Profit Margin (Net Kâr Marjı)
-891.6%
-48.4%
ROA
-55.5%
-28.4%
ROE
152.7%
-49.2%
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
Metrik
5 Yıllık trend
CYTK
Akran Ortalaması
Debt / Equity (Borç / Öz Sermaye)
-0.4
—
Current Ratio (Cari Oran)
4.5
5.0
Quick Ratio (Cari Oran)
0.7
—
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
Metrik
5 Yıllık trend
CYTK
Akran Ortalaması
Revenue YoY (Gelir Yıllık Bazda)
376.6%
—
Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı)
-2.4%
—
Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı)
9.5%
—
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
Metrik
5 Yıllık trend
CYTK
Akran Ortalaması
CYTK Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
AL
28 analist
- Güçlü Al 6 21,4%
- Al 19 67,9%
- Tut 3 10,7%
- Sat 0 0,0%
- Güçlü Sat 0 0,0%
12 Aylık Fiyat Hedefi
20 analist · 2026-08-18
Medyan
$107.50
← Tüm hedeflerin altında
$76.67
Düşük
$85.00
Yüksek
$146.00
Medyan hedef
$107.50
+40,2%
Ortalama hedef
$109.90
+43,3%
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
-0.08%
| Dönem | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|
| 30 Haziran 2026 | $-1.50 | $-1.67 | 0.17% |
| 31 Mart 2026 | $-1.67 | $-1.69 | 0.02% |
| 31 Aralık 2025 | $-1.50 | $-1.49 | -0.01% |
| 30 Eylül 2025 | $-2.55 | $-1.61 | -0.94% |
| 30 Haziran 2025 | $-1.12 | $-1.41 | 0.28% |
| 31 Mart 2025 | $-1.39 | $-1.41 | 0.02% |
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | — |
| EXEL | $11.44B | 15.7 | 7.0% | 33.7% | 37.3% | — |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | — |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | — |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | — |
| PRAX | $7.43B | -21.9 | 249.5% | — | -47.3% | — |
| SMMT | $13.56B | -12.1 | — | — | -235.1% | — |
| PTGX | $5.47B | -42.6 | -89.4% | -282.8% | -20.3% | — |
| KYMR | $6.33B | -21.1 | -16.7% | -794.0% | -24.4% | — |
| APGE | $5.16B | -17.9 | — | — | — | — |
| KRYS | $7.20B | 36.0 | 33.9% | 52.6% | 18.1% | — |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu 16
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M | $29M | $47M | |
| R&D Expense | $416M | $339M | $330M | $241M | $160M | $97M | $86M | $89M | $90M | $60M | $46M | $44M | |
| SG&A Expense | $284M | $215M | $174M | $178M | $97M | $53M | $40M | $31M | $36M | $28M | $20M | $17M | |
| Operating Expenses | $700M | $555M | $504M | $419M | $257M | $150M | $126M | $120M | $127M | $88M | $66M | $62M | |
| Operating Income | $-612M | $-536M | $-496M | $-324M | $-186M | $-94M | $-99M | $-89M | $-113M | $19M | $-37M | $-15M | |
| Interest Expense | $46M | $38M | $28M | $19M | $16M | $16M | $7M | $4M | $3M | $3M | $268.0K | $0 | |
| Interest Income | · | · | · | $11M | $1M | $5M | $4M | $4M | · | $449.0K | $156.0K | $101.0K | |
| Other Non-op | $48M | $52M | $28M | $11M | $331.0K | $5M | $5M | $4M | $3M | $464.0K | $174.0K | $108.0K | |
| Pretax Income | · | · | · | · | · | · | · | $-106M | $-128M | $16M | $-38M | $-15M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-785M | $-590M | $-526M | $-389M | $-215M | $-127M | $-122M | $-106M | $-128M | $16M | $-38M | $-15M | |
| EPS (Basic) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.41 | $-0.97 | $-0.41 | |
| EPS (Diluted) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.39 | $-0.97 | $-0.41 | |
| Shares (Basic) | 120,103 | 111,979 | 96,524 | 89,825 | 76,886 | 64,524 | · | · | 49,404,000 | 39,943,000 | 38,814,000 | 35,709,000 | |
| Shares (Diluted) | 120,103 | 111,979 | 96,524 | 89,825 | 76,886 | 64,524 | · | · | 49,404,000 | 42,561,000 | 38,814,000 | 35,709,000 | |
| EBITDA | $-602M | $-527M | $-484M | $-318M | $-184M | $-92M | $-98M | $-88M | $-111M | $19M | $-37M | $-14M |
Bilanço 26
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $123M | $95M | $113M | $66M | $113M | $83M | $36M | $42M | $125M | $67M | $65M | $20M | |
| Receivables | $18M | $17M | $1M | $147.0K | $52M | $4M | $5M | $2M | $1M | $24.0K | · | · | |
| Inventory | $0 | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $17M | $15M | $12M | $12M | $12M | $6M | $3M | $2M | $4M | $2M | $2M | $1M | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | · | · | $1M | |
| Current Assets | $917M | $1.11B | $628M | $795M | $536M | $474M | $234M | $208M | $274M | $159M | $113M | $131M | |
| PP&E (Net) | $79M | $66M | $69M | $80M | $73M | $13M | $5M | $3M | $4M | $4M | $2M | $2M | |
| PP&E (Gross) | $126M | $103M | $97M | $98M | $89M | $38M | $29M | $27M | $26M | $25M | $23M | $22M | |
| Accum. Depreciation | $47M | $37M | $28M | $17M | $16M | $25M | $24M | $24M | $23M | $21M | $21M | $20M | |
| Other Non-current Assets | $17M | $8M | $8M | $10M | $7M | $6M | · | $300.0K | $429.0K | $200.0K | $200.0K | $200.0K | |
| Total Assets | $1.42B | $1.40B | $824M | $1.01B | $841M | $534M | $290M | $211M | $295M | $170M | $115M | $133M | |
| Accounts Payable | $22M | $20M | $22M | $26M | $21M | $8M | $8M | $4M | $5M | $4M | $2M | $1M | |
| Accrued Liabilities | $83M | $55M | $43M | $44M | $34M | $19M | $12M | $16M | $17M | $18M | $8M | $5M | |
| Current Liabilities | $202M | $180M | $103M | $85M | $72M | $31M | $26M | $22M | $32M | $33M | $32M | $24M | |
| Capital Leases | $108M | $113M | $120M | $127M | $112M | $440.0K | $2M | $771.0K | · | · | · | · | |
| Other Non-current Liabilities | · | $0 | $186.0K | $1M | $4M | $0 | · | $771.0K | $1M | $142.0K | · | · | |
| Total Liabilities | $2.08B | $1.54B | $1.21B | $1.12B | $597M | $420M | $301M | $185M | $185M | $76M | $47M | $41M | |
| Long-term Debt | $288M | $620M | $639M | $650M | · | $46M | $45M | $42M | $32M | $30M | $15M | · | |
| Total Debt | $288M | $105M | $68M | $64M | $47M | $46M | $45M | $42M | $32M | $30M | $15M | · | |
| Common Stock | $123.0K | $118.0K | $102.0K | $94.0K | $84.0K | $70.0K | $59.0K | $55.0K | $54.0K | $41.0K | $40.0K | $39.0K | |
| Paid-in Capital | · | · | · | · | $1.45B | · | · | · | · | · | · | $589M | |
| Retained Earnings | $-3.49B | $-2.70B | $-2.11B | $-1.59B | $-1.21B | $-992M | $-865M | $-743M | $-646M | $-518M | $-535M | $-497M | |
| AOCI | $630.0K | $2M | $-10.0K | $-4M | $-869.0K | $149.0K | $679.0K | $500.0K | $343.0K | $137.0K | $149.0K | $-4.0K | |
| Stockholders' Equity | $-660M | $-135M | $-386M | $-108M | $244M | $113M | $-11M | $26M | $110M | $94M | $69M | $92M | |
| Liabilities + Equity | $1.42B | $1.40B | $824M | $1.01B | $841M | $534M | $290M | $211M | $295M | $170M | $115M | $133M | |
| Shares Outstanding | 122,943,172 | 118,209,139 | 101,637,922 | 94,833,975 | 84,799,542 | 71,015,183 | 59,172,124 | 54,717,906 | 53,960,832 | 40,646,595 | 39,581,692 | 38,659,738 |
Nakit Akışı 16
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $10M | $10M | $12M | $6M | $2M | $2M | $1M | $1M | $2M | $741.0K | $589.0K | $490.0K | |
| Stock-based Comp | $112M | $98M | $72M | $48M | $27M | $18M | $11M | $10M | $9M | $7M | $5M | $3M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Other Non-cash | $153M | $86M | $28M | $36M | $44M | $117M | $19M | $-6M | $15M | $13M | $37M | $-34M | |
| Operating Cash Flow | $-510M | $-396M | $-414M | $-300M | $-143M | $9M | $-91M | $-101M | $-102M | $37M | $5M | $-45M | |
| CapEx | $25M | $4M | $1M | $11M | $49M | $11M | $3M | $889.0K | $3M | $2M | $562.0K | $1M | |
| Investing Cash Flow | $17M | $-553M | $239M | $-262M | $-148M | $-197M | $-75M | $5M | $-66M | · | · | · | |
| Net Debt Issued | $-11M | $-9M | · | $-48M | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | $164M | · | $0 | $0 | $36M | $0 | $112M | $0 | $9M | $49M | |
| Net Stock Activity | · | · | $164M | · | $0 | $0 | $36M | $0 | $112M | $0 | $9M | $49M | |
| Financing Cash Flow | $524M | $931M | $221M | $516M | $320M | $234M | $160M | $13M | $226M | · | · | · | |
| Net Change in Cash | $30M | $-18M | $46M | $-45M | $30M | $47M | $-6M | $-83M | $58M | $2M | $45M | $57.0K | |
| Taxes Paid | $0 | $0 | $0 | · | · | · | · | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | |
| Free Cash Flow | $-535M | $-400M | $-416M | $-311M | $-191M | $-2M | $-94M | $-102M | $-105M | $35M | $4M | $-46M | |
| Levered FCF | · | · | · | · | · | · | · | $-106M | $-108M | $33M | · | $-46M |
Kârlılık 7
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% | -168.3% | -368.0% | -282.3% | -848.3% | 17.6% | -130.5% | -31.4% | |
| Net Margin | -891.6% | -3191.1% | -6988.6% | -411.2% | -305.7% | -228.0% | -452.9% | -337.4% | -955.9% | 15.5% | -130.9% | -31.2% | |
| Pretax Margin | · | · | · | · | · | · | · | -337.4% | -955.9% | 15.5% | -130.9% | -31.2% | |
| EBITDA Margin | -683.9% | -2851.1% | -6431.8% | -336.6% | -261.3% | -165.0% | -363.2% | -278.3% | -833.9% | 18.3% | -128.5% | -30.4% | |
| ROA | -55.5% | -53.0% | -57.2% | -41.9% | -31.3% | -30.9% | -48.6% | -42.0% | -55.0% | 11.5% | -30.2% | -13.6% | |
| ROE | 152.7% | 789.8% | 127.6% | 628.0% | -87.4% | -96.8% | 790.0% | -272.5% | -125.2% | 20.2% | -46.7% | -20.0% | |
| ROIC | · | · | · | · | · | · | · | -130.1% | -80.1% | 15.0% | -44.9% | -16.0% |
Likidite ve Solventlik 5
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.5 | 6.2 | 6.1 | 9.4 | 7.5 | 15.2 | 9.0 | 9.4 | 8.5 | 4.8 | 3.6 | 5.5 | |
| Quick Ratio | 0.7 | 0.6 | 1.1 | 0.8 | 2.3 | 2.8 | 1.6 | 2.0 | 3.9 | 2.0 | 2.1 | 0.8 | |
| Debt / Equity | -0.4 | -0.8 | -0.2 | -0.6 | 0.2 | 0.4 | -4.1 | 1.6 | 0.3 | 0.3 | 0.2 | · | |
| LT Debt / Equity | -0.4 | -0.7 | -0.2 | -0.6 | 0.2 | 0.4 | -4.1 | 1.5 | 0.3 | 0.3 | 0.2 | · | |
| Interest Coverage | -13.4 | -14.2 | -17.5 | -16.7 | -11.3 | -5.9 | -14.9 | -23.4 | -37.6 | 6.9 | · | · |
Verimlilik 2
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.7 | 0.2 | 0.4 | |
| Receivables Turnover | 5.1 | 2.1 | 10.5 | 3.6 | 2.5 | 11.7 | 7.3 | 18.8 | 23.5 | · | · | · |
Büyüme Oranları 3
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 376.6% | 145.3% | -92.0% | 34.3% | 26.2% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -2.4% | -36.0% | -48.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 9.5% | · | · | · | · | · | · | · | · | · | · | · |
Değerleme (TTM) 14
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M | $29M | $47M | |
| Net Income TTM | $-785M | $-590M | $-526M | $-389M | $-215M | $-127M | $-122M | $-106M | $-128M | $16M | $-38M | $-15M | |
| Market Cap | $7.81B | $5.56B | $8.49B | $4.35B | $3.87B | $1.48B | $628M | $346M | $440M | $494M | $414M | $310M | |
| Enterprise Value | $7.98B | $5.57B | $8.44B | $4.34B | $3.80B | $1.44B | $636M | $346M | $346M | $457M | $364M | · | |
| P/E | -9.7 | -8.9 | -15.3 | -10.6 | -16.3 | -10.5 | · | · | -3.1 | 31.2 | -10.8 | -19.5 | |
| P/S | 88.7 | 301.0 | 1126.9 | 45.9 | 54.9 | 26.4 | 23.4 | 11.0 | 32.9 | 4.6 | 14.4 | 6.6 | |
| P/B | -11.8 | -41.1 | -22.0 | -40.3 | 15.8 | 13.0 | -57.4 | 13.3 | 4.0 | 5.2 | 6.0 | 3.4 | |
| P / Tangible Book | · | · | · | · | 15.8 | 13.0 | · | · | · | · | · | · | |
| P / Cash Flow | -15.3 | -14.0 | -20.5 | -14.5 | -27.1 | 165.0 | -6.9 | -3.4 | -4.3 | 13.4 | 84.8 | -6.9 | |
| P / FCF | -14.6 | -13.9 | -20.4 | -14.0 | -20.2 | -699.7 | -6.7 | -3.4 | -4.2 | 14.0 | 95.8 | -6.7 | |
| EV / EBITDA | -13.2 | -10.6 | -17.4 | -13.6 | -20.6 | -15.6 | -6.5 | -3.9 | -3.1 | 23.5 | -9.9 | · | |
| EV / FCF | -14.9 | -13.9 | -20.3 | -14.0 | -19.9 | -682.3 | -6.8 | -3.4 | -3.3 | 12.9 | 84.1 | · | |
| EV / Revenue | 90.6 | 301.5 | 1121.0 | 45.9 | 54.0 | 25.8 | 23.7 | 11.0 | 25.9 | 4.3 | 12.7 | · | |
| Earnings Yield | -10.3% | -11.2% | -6.5% | -9.4% | -6.1% | -9.5% | · | · | -31.8% | 3.2% | -9.3% | -5.1% |
Gelir Tablosu 14
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29M | $19M | $18M | $2M | $67M | $2M | $17M | $463.0K | $249.0K | $835.0K | $2M | $378.0K | $867.0K | $5M | $2M | $3M | |
| R&D Expense | $98M | $96M | $104M | $99M | $110M | $98M | $94M | $85M | $80M | $82M | $85M | $83M | $83M | $79M | $75M | $63M | |
| SG&A Expense | $104M | $105M | $92M | $69M | $66M | $57M | $62M | $57M | $51M | $46M | $44M | $40M | $40M | $50M | $54M | $48M | |
| Operating Expenses | $208M | $203M | $196M | $169M | $178M | $157M | $156M | $141M | $130M | $127M | $129M | $123M | $123M | $129M | $129M | $111M | |
| Operating Income | $-179M | $-184M | $-178M | $-167M | $-112M | $-156M | $-139M | $-141M | $-130M | $-126M | $-127M | $-122M | $-122M | $-124M | $-127M | $-108M | |
| Interest Expense | · | · | $14M | $11M | $11M | · | $9M | $9M | $13M | $7M | $7M | $7M | $7M | $7M | $7M | $7M | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $4M | |
| Other Non-op | $14M | $11M | $11M | $10M | $13M | $14M | $15M | $17M | $12M | $8M | $8M | $7M | $7M | $6M | $6M | $4M | |
| Net Income | $-199M | $-206M | $-183M | $-306M | $-134M | $-161M | $-150M | $-161M | $-143M | $-136M | $-137M | $-129M | $-129M | $-131M | $-137M | $-142M | |
| EPS (Basic) | $-1.50 | $-1.67 | $-1.51 | $-2.55 | $-1.12 | $-1.36 | $-1.26 | $-1.36 | $-1.31 | $-1.33 | $-1.38 | $-1.35 | $-1.34 | $-1.38 | $-1.53 | $-1.52 | |
| EPS (Diluted) | $-1.50 | $-1.67 | $-1.51 | $-2.55 | $-1.12 | $-1.36 | $-1.26 | $-1.36 | $-1.31 | $-1.33 | $-1.38 | $-1.35 | $-1.34 | $-1.38 | $-1.53 | $-1.52 | |
| Shares (Basic) | 132,086 | 123,273 | -237,832 | 119,982 | 119,457 | 118,496 | -216,870 | 117,685 | 109,240 | 101,924 | -190,466 | 96,071 | 95,755 | 95,164 | -174,660 | 93,758 | |
| Shares (Diluted) | 132,086 | 123,273 | -237,832 | 119,982 | 119,457 | 118,496 | -216,870 | 117,685 | 109,240 | 101,924 | -190,466 | 96,071 | 95,755 | 95,164 | -174,660 | 93,758 | |
| EBITDA | $-179M | $-180M | · | $-167M | $-112M | $-153M | · | $-141M | $-130M | $-124M | · | $-122M | $-122M | $-123M | · | $-108M |
Bilanço 24
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $255M | $130M | $123M | $225M | $75M | $74M | $95M | $47M | $190M | $120M | · | $100M | $69M | $102M | · | $106M | |
| Receivables | $24M | $7M | $18M | $2M | $8M | $2M | $17M | $244.0K | $0 | $834.0K | · | $2M | $985.0K | $1M | · | $2M | |
| Inventory | $380.0K | $154.0K | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $18M | $14M | $17M | $13M | $20M | $16M | $15M | $7M | $11M | $19M | · | $20M | $20M | $16M | · | $14M | |
| Current Assets | $1.21B | $839M | $917M | $977M | $887M | $956M | $1.11B | $1.02B | $1.07B | $639M | · | $561M | $587M | $681M | · | $884M | |
| PP&E (Net) | $79M | $82M | $79M | $76M | $70M | $67M | $66M | $64M | $66M | $68M | · | $76M | $77M | $79M | · | $80M | |
| PP&E (Gross) | · | · | $126M | · | · | · | $103M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $47M | · | · | · | $37M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $19M | $18M | $17M | $17M | $15M | $13M | $8M | $8M | $8M | $8M | · | $8M | $8M | $8M | · | · | |
| Total Assets | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808M | · | $741M | $780M | $890M | · | $1.08B | |
| Accounts Payable | $21M | $25M | $22M | $22M | $16M | $14M | $20M | $12M | $9M | $13M | · | $14M | $13M | $17M | · | $14M | |
| Accrued Liabilities | $77M | $69M | $83M | $62M | $52M | $43M | $55M | $50M | $40M | $40M | · | $33M | $31M | $36M | · | $40M | |
| Current Liabilities | $181M | $199M | $202M | $142M | $131M | $160M | $180M | $110M | $103M | $89M | · | $78M | $66M | $75M | · | $76M | |
| Capital Leases | $102M | $105M | $108M | $111M | $111M | $113M | $113M | $115M | $117M | $119M | · | $122M | $124M | $125M | · | $114M | |
| Other Non-current Liabilities | · | · | · | $2M | $2M | $3M | · | $0 | $0 | $2.0K | · | $408.0K | $625.0K | $837.0K | · | $1M | |
| Total Liabilities | $2.10B | $2.10B | $2.08B | $1.96B | $1.59B | $1.53B | $1.54B | $1.45B | $1.42B | $1.20B | · | $1.18B | $1.11B | $1.12B | · | $1.09B | |
| Long-term Debt | $276M | $292M | $288M | $1.00B | $610M | $610M | $105M | $620M | $629M | $630M | · | · | · | · | · | · | |
| Total Debt | $276M | $292M | · | $176M | $173M | $105M | · | $105M | $104M | $68M | · | $61M | $62M | $64M | · | $64M | |
| Common Stock | $138.0K | $124.0K | $123.0K | $122.0K | $119.0K | $119.0K | $118.0K | $118.0K | $117.0K | $105.0K | · | $94.0K | $94.0K | $94.0K | · | $93.0K | |
| Retained Earnings | $-3.89B | $-3.69B | $-3.49B | $-3.30B | $-3.00B | $-2.86B | $-2.70B | $-2.55B | $-2.39B | $-2.25B | · | $-1.98B | $-1.85B | $-1.72B | · | $-1.45B | |
| AOCI | $-4M | $-2M | $630.0K | $34.0K | $-158.0K | $2M | $2M | $5M | $-1M | $-539.0K | · | $-874.0K | $-1M | $-2M | · | $-6M | |
| Stockholders' Equity | $-173M | $-827M | $-660M | $-521M | $-369M | $-266M | $-135M | $-14M | $109M | $-396M | $-386M | $-439M | $-333M | $-229M | $-108M | $-16M | |
| Liabilities + Equity | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808M | · | $741M | $780M | $890M | · | $1.08B | |
| Shares Outstanding | · | · | 122,943,172 | · | · | · | 118,209,139 | · | · | · | · | · | · | · | · | · |
Nakit Akışı 12
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $6M | $2M | $2M | $2M | $2M | $1M | |
| Stock-based Comp | $36M | $30M | $31M | $31M | $28M | $24M | $26M | $25M | $25M | $22M | $19M | $19M | $19M | $15M | $13M | $13M | |
| Other Non-cash | · | $27M | · | · | · | $4M | · | · | · | $-18M | · | · | · | $-8M | · | · | |
| Operating Cash Flow | $-160M | $-145M | $-143M | $-108M | $-128M | $-132M | $-66M | $-102M | $-99M | $-130M | $-74M | $-96M | $-122M | $-122M | $-98M | $-84M | |
| CapEx | $4M | $6M | $6M | $9M | $4M | $6M | $1M | $701.0K | $2M | $0 | $77.0K | $220.0K | $717.0K | $402.0K | $3M | $6M | |
| Investing Cash Flow | $-507M | $145M | $-71M | $-71M | $53M | $106M | $111M | $-45M | $-652M | $33M | $-81M | $73M | $82M | $165M | $29M | $-292M | |
| Net Debt Issued | · | $-3M | · | · | · | $-3M | · | · | · | $-705.0K | · | · | · | · | · | · | |
| Stock Issued | · | · | · | · | $0 | $0 | · | · | · | $94M | · | · | · | $0 | · | · | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $94M | · | · | · | · | · | · | |
| Financing Cash Flow | $793M | $8M | $111M | $330M | $79M | $5M | $2M | $3M | $821M | $104M | $169M | $54M | $5M | $-7M | $30M | $389M | |
| Net Change in Cash | $125M | $7M | $-103M | $152M | $2M | $-21M | $48M | $-143M | $70M | $7M | $13M | $31M | $-34M | $36M | $-39M | $13M | |
| Free Cash Flow | · | $-151M | · | · | · | $-137M | · | · | · | $-130M | · | · | · | $-123M | · | · |
Kârlılık 5
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -626.0% | -948.7% | · | -8613.4% | -167.0% | -9856.3% | · | -30410.6% | -52277.9% | -15118.0% | · | -32345.2% | -14077.2% | -2698.3% | · | -4311.8% | |
| Net Margin | -694.4% | -1064.5% | · | -15815.0% | -201.3% | -10220.1% | · | -34675.0% | -57557.4% | -16244.7% | · | -34238.6% | -14837.0% | -2846.1% | · | -5658.4% | |
| EBITDA Margin | -626.0% | -931.2% | · | -8613.4% | -167.0% | -9710.6% | · | -30410.6% | -52277.9% | -14838.8% | · | -32345.2% | -14077.2% | -2658.2% | · | -4311.8% | |
| ROA | -12.6% | -16.2% | · | -21.3% | -9.8% | -15.6% | · | -14.8% | -12.4% | -16.0% | · | -14.2% | -16.6% | -15.0% | · | -14.9% | |
| ROE | 73.3% | 37.7% | · | 114.5% | 103.3% | 48.7% | · | 70.9% | 127.6% | 43.4% | · | 56.9% | 116.1% | 232.9% | · | -122.1% |
Likidite ve Solventlik 5
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.7 | 4.2 | · | 6.9 | 6.8 | 6.0 | · | 9.3 | 10.4 | 7.2 | · | 7.2 | 8.9 | 9.0 | · | 11.6 | |
| Quick Ratio | 1.5 | 0.7 | · | 1.6 | 0.6 | 0.5 | · | 0.4 | 1.9 | 1.4 | · | 1.3 | 1.1 | 1.4 | · | 1.4 | |
| Debt / Equity | -1.6 | -0.4 | · | -0.3 | -0.5 | -0.4 | · | -7.5 | 1.0 | -0.2 | · | -0.1 | -0.2 | -0.3 | · | -4.0 | |
| LT Debt / Equity | -1.4 | -0.3 | · | -0.3 | -0.4 | -0.3 | · | -6.7 | 0.9 | -0.1 | · | -0.1 | -0.2 | -0.3 | · | -4.0 | |
| Interest Coverage | · | · | · | -14.7 | -10.1 | · | · | -15.8 | -10.2 | -17.8 | · | -17.1 | -17.3 | -17.9 | · | -15.9 |
Verimlilik 2
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 1.7 | 4.4 | · | 1.9 | 15.9 | 1.1 | · | 0.3 | 0.5 | 0.9 | · | 0.2 | 0.6 | 1.3 | · | 1.7 |
Değerleme (TTM) 4
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $117M | $90M | · | $71M | $69M | $3M | · | $2M | $2M | $7M | · | $8M | $97M | $97M | · | $98M | |
| Net Income TTM | $-845M | $-808M | · | $-762M | $-600M | $-601M | · | $-569M | $-537M | $-525M | · | $-532M | $-422M | $-383M | · | $-328M | |
| P/E | -12.5 | -9.8 | · | -8.6 | -6.4 | -7.5 | · | -9.9 | -10.2 | -13.0 | · | -5.3 | -7.3 | -8.4 | · | -12.9 | |
| Earnings Yield | -8.0% | -10.2% | · | -11.6% | -15.6% | -13.3% | · | -10.1% | -9.8% | -7.7% | · | -19.0% | -13.7% | -11.9% | · | -7.7% |
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
Gelir Tablosu
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Gelir | $88M | $18M | $8M | $95M | $70M |
| Faaliyet Kâr Marjı % | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% |
| Net Gelir | $-785M | $-590M | $-526M | $-389M | $-215M |
| Seyreltilmiş Hisse Başı Kâr | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 |
Bilanço
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Borç / Öz Sermaye | -0.4 | -0.8 | -0.2 | -0.6 | 0.2 |
| Cari Oran | 4.5 | 6.2 | 6.1 | 9.4 | 7.5 |
| Cari Oran | 0.7 | 0.6 | 1.1 | 0.8 | 2.3 |
Nakit Akışı
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $-535M | $-400M | $-416M | $-311M | $-191M |
Son Haberler Bu şirketten bahseden son manşetler
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
📊
Sizin için önemli olan metrikleri seçin — yukarıdaki Tam Temeller'deki herhangi bir satırın yanındaki ➕ düğmesine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kurumsal Sahipler (13F) 540 dosya · $9.0B toplam · Tarih itibarıyla 30 Haziran 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 104 (0 önceki Ç'ye göre) | 49 (-6 önceki Ç'ye göre) | 222 (+43 önceki Ç'ye göre) | 112 (-32 önceki Ç'ye göre) | +5.3M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| VANGUARD PORTFOLIO MANAGEMENT LLC | $571.778.157 | 6.711.799 | 6,37% | Hisse senetleri |
| STATE STREET CORP | $553.243.709 | 6.494.233 | 6,16% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $521.151.103 | 6.117.515 | 5,80% | Hisse senetleri |
| WELLINGTON MANAGEMENT GROUP LLP | $509.521.049 | 5.980.996 | 5,67% | Hisse senetleri |
| Avoro Capital Advisors LLC | $425.949.915 | 4.999.999 | 4,74% | Hisse senetleri |
| FMR LLC | $375.035.430 | 4.402.341 | 4,18% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $259.207.450 | 3.042.018 | 2,89% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $251.706.463 | 2.954.648 | 2,80% | Hisse senetleri |
| RTW INVESTMENTS, LP | $243.814.036 | 2.862.003 | 2,72% | Hisse senetleri |
| Polar Capital Holdings Plc | $191.988.358 | 2.253.649 | 2,14% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $161.060.214 | 1.890.600 | 1,79% | Alım opsiyonu |
| Capital Research Global Investors | $143.683.584 | 1.686.625 | 1,60% | Hisse senetleri |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $136.597.224 | 1.603.442 | 1,52% | Hisse senetleri |
| Integral Health Asset Management, LLC | $136.304.000 | 1.600.000 | 1,52% | Hisse senetleri |
| Point72 Asset Management, L.P. | $135.257.185 | 1.587.712 | 1,51% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $133.386.924 | 1.565.758 | 1,49% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $131.998.327 | 1.549.458 | 1,47% | Hisse senetleri |
| PRINCIPAL FINANCIAL GROUP INC | $111.435.932 | 1.308.087 | 1,24% | Hisse senetleri |
| Capital International Investors | $111.245.191 | 1.305.848 | 1,24% | Hisse senetleri |
| ARMISTICE CAPITAL, LLC | $106.487.500 | 1.250.000 | 1,19% | Alım opsiyonu |
| ARMISTICE CAPITAL, LLC | $102.342.325 | 1.201.342 | 1,14% | Hisse senetleri |
| Pictet Asset Management Holding SA | $99.038.455 | 1.160.463 | 1,10% | Hisse senetleri |
| Frazier Life Sciences Management, L.P. | $98.810.092 | 1.159.879 | 1,10% | Hisse senetleri |
| Holocene Advisors, LP | $97.506.685 | 1.144.579 | 1,09% | Hisse senetleri |
| Woodline Partners LP | $93.769.315 | 1.100.708 | 1,04% | Hisse senetleri |
| NORGES BANK | $86.512.319 | 1.015.522 | 0,96% | Hisse senetleri |
| Royalty Pharma Sub-Manager, LLC | $83.519.594 | 980.392 | 0,93% | Hisse senetleri |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $81.937.000 | 961.815 | 0,91% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $77.218.175 | 906.423 | 0,86% | Hisse senetleri |
| CITADEL ADVISORS LLC | $77.062.874 | 904.600 | 0,86% | Alım opsiyonu |
| Melqart Asset Management (UK) Ltd | $65.385.455 | 767.525 | 0,73% | Hisse senetleri |
| Siren, L.L.C. | $64.655.121 | 758.952 | 0,72% | Hisse senetleri |
| Fisher Asset Management, LLC | $63.355.547 | 743.697 | 0,71% | Hisse senetleri |
| Foresite Capital Management IV, LLC | $60.884.867 | 714.695 | 0,68% | Hisse senetleri |
| Balyasny Asset Management L.P. | $60.599.821 | 711.349 | 0,67% | Hisse senetleri |
| Deep Track Capital, LP | $59.633.000 | 700.000 | 0,66% | Hisse senetleri |
| JANE STREET GROUP, LLC | $59.633.000 | 700.000 | 0,66% | Alım opsiyonu |
| BNP PARIBAS FINANCIAL MARKETS | $58.702.470 | 689.077 | 0,65% | Hisse senetleri |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. | $56.251.809 | 660.310 | 0,63% | Hisse senetleri |
| CITADEL ADVISORS LLC | $54.601.338 | 640.936 | 0,61% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $54.053.311 | 634.503 | 0,60% | Hisse senetleri |
| Qube Research & Technologies Ltd | $48.774.257 | 572.535 | 0,54% | Hisse senetleri |
| EVENTIDE ASSET MANAGEMENT, LLC | $48.081.832 | 564.398 | 0,54% | Hisse senetleri |
| Affinity Asset Advisors, LLC | $46.854.500 | 550.000 | 0,52% | Hisse senetleri |
| First Turn Management, LLC | $44.930.228 | 527.412 | 0,50% | Hisse senetleri |
| AMERICAN CENTURY COMPANIES INC | $44.162.525 | 518.398 | 0,49% | Hisse senetleri |
| Caption Management, LLC | $43.651.356 | 512.400 | 0,49% | Alım opsiyonu |
| D. E. Shaw & Co., Inc. | $40.874.247 | 479.801 | 0,46% | Hisse senetleri |
| Checkpoint Capital L.P. | $40.465.250 | 475.000 | 0,45% | Hisse senetleri |
| Hood River Capital Management LLC | $39.977.367 | 469.273 | 0,45% | Hisse senetleri |
| RP Management, LLC | $39.401.954 | 980.392 | 0,44% | Hisse senetleri |
| EMERALD ADVISERS, LLC | $39.013.272 | 457.956 | 0,43% | Hisse senetleri |
| ADAR1 Capital Management, LLC | $39.009.097 | 457.907 | 0,43% | Hisse senetleri |
| AMERIPRISE FINANCIAL INC | $38.010.006 | 446.179 | 0,42% | Hisse senetleri |
| Candriam S.C.A. | $37.708.477 | 443.066 | 0,42% | Hisse senetleri |
| MARSHALL WACE, LLP | $36.259.335 | 425.629 | 0,40% | Hisse senetleri |
| RHUMBLINE ADVISERS | $35.933.015 | 421.799 | 0,40% | Hisse senetleri |
| CITADEL ADVISORS LLC | $35.882.028 | 421.200 | 0,40% | Satım opsiyonu |
| ALLIANCEBERNSTEIN L.P. | $35.327.299 | 535.993 | 0,39% | Hisse senetleri |
| GILDER GAGNON HOWE & CO LLC | $34.096.829 | 400.245 | 0,38% | Hisse senetleri |
| TD Asset Management Inc | $32.809.225 | 385.130 | 0,37% | Hisse senetleri |
| BlackRock, Inc. | $29.124.928 | 341.882 | 0,32% | Hisse senetleri |
| GSK plc | $29.001.573 | 340.434 | 0,32% | Hisse senetleri |
| TWO SIGMA INVESTMENTS, LP | $27.040.243 | 317.411 | 0,30% | Hisse senetleri |
| CITIGROUP INC | $26.852.314 | 315.205 | 0,30% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $24.671.024 | 289.600 | 0,27% | Satım opsiyonu |
| Trails Edge Capital Partners, LP | $24.542.302 | 288.089 | 0,27% | Hisse senetleri |
| EMERALD MUTUAL FUND ADVISERS TRUST | $23.833.521 | 279.769 | 0,27% | Hisse senetleri |
| Polaris Capital Management, LLC | $22.737.211 | 266.900 | 0,25% | Hisse senetleri |
| SEGALL BRYANT & HAMILL, LLC | $21.899.197 | 257.063 | 0,24% | Hisse senetleri |
| Alyeska Investment Group, L.P. | $21.297.500 | 250.000 | 0,24% | Hisse senetleri |
| ExodusPoint Capital Management, LP | $21.234.374 | 249.259 | 0,24% | Hisse senetleri |
| Capital World Investors | $21.196.550 | 248.815 | 0,24% | Hisse senetleri |
| Walleye Capital LLC | $20.422.428 | 239.728 | 0,23% | Hisse senetleri |
| E. Ohman J:or Asset Management AB | $19.823.223 | 300.762 | 0,22% | Hisse senetleri |
| Sarissa Capital Management LP | $19.476.393 | 228.623 | 0,22% | Hisse senetleri |
| Swiss National Bank | $18.946.256 | 222.400 | 0,21% | Hisse senetleri |
| SPHERA FUNDS MANAGEMENT LTD. | $18.740.693 | 219.987 | 0,21% | Hisse senetleri |
| BAKER BROS. ADVISORS LP | $17.997.836 | 211.267 | 0,20% | Hisse senetleri |
| California Public Employees Retirement System | $17.979.520 | 211.052 | 0,20% | Hisse senetleri |
| Nicholas Investment Partners, LP | $17.810.758 | 209.071 | 0,20% | Hisse senetleri |
| PINNACLE ASSOCIATES LTD | $17.245.864 | 202.440 | 0,19% | Hisse senetleri |
| Mirador Capital Partners LP | $17.239.900 | 202.370 | 0,19% | Hisse senetleri |
| Tri Locum Partners LP | $16.526.860 | 194.000 | 0,18% | Hisse senetleri |
| PFM Health Sciences, LP | $16.329.730 | 191.686 | 0,18% | Hisse senetleri |
| Rock Springs Capital Management LP | $16.014.016 | 187.980 | 0,18% | Hisse senetleri |
| PRUDENTIAL FINANCIAL INC | $15.933.512 | 187.035 | 0,18% | Hisse senetleri |
| DAFNA Capital Management LLC | $14.652.510 | 171.998 | 0,16% | Hisse senetleri |
| Ghisallo Capital Management LLC | $14.482.300 | 170.000 | 0,16% | Hisse senetleri |
| Impax Asset Management Group plc | $14.056.350 | 165.000 | 0,16% | Hisse senetleri |
| Lombard Odier Asset Management (Europe) Ltd | $13.494.096 | 158.400 | 0,15% | Alım opsiyonu |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | $13.383.349 | 157.100 | 0,15% | Hisse senetleri |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $13.330.276 | 156.477 | 0,15% | Hisse senetleri |
| JANE STREET GROUP, LLC | $12.735.905 | 149.500 | 0,14% | Satım opsiyonu |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $12.145.719 | 139.190 | 0,14% | Hisse senetleri |
| Retirement Systems of Alabama | $11.962.891 | 140.426 | 0,13% | Hisse senetleri |
| MetLife Investment Management, LLC | $11.930.519 | 140.046 | 0,13% | Hisse senetleri |
| Polymer Capital Management (HK) LTD | $11.777.943 | 138.255 | 0,13% | Hisse senetleri |
| Cinctive Capital Management LP | $11.742.419 | 137.838 | 0,13% | Hisse senetleri |
| TUDOR INVESTMENT CORP ET AL | $11.279.156 | 132.400 | 0,13% | Alım opsiyonu |
Şirket yöneticileri 52 içeriden öğrenenler · 18 yöneticiler · 22 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Sung Lee | EVP, Chief Financial Officer | 01 Temmuz 2026 M | 63.221 | 0 | 5 | $-5.695.855 |
| Ching Jaw | SVP Finance & CFO | 06 Mart 2023 A | 87.346 | 0 | 0 | $0 |
| Sharon Surrey Barbari | EVP, Finance & CFO | 28 Şubat 2017 F | 40.323 | 0 | 0 | $0 |
| Fady Ibraham Malik | EVP Research & Development | 18 Ağustos 2026 M | 153.902 | 0 | 21 | $-4.352.750 |
| Andrew Callos | EVP, Chief Commercial Officer | 30 Temmuz 2026 M | 58.555 | 0 | 24 | $-15.318.893 |
| Jeffrey Hessekiel | Chief Legal & Admin Officer | 15 Mart 2026 A | 107.943 | 0 | 0 | $0 |
| Robert Wong | VP, Chief Accounting Officer | 03 Aralık 2024 A | 18.655 | 0 | 0 | $0 |
| Brett A Pletcher | EVP, Chief Legal Officer | 30 Ağustos 2024 A | 33.140 | 0 | 0 | $0 |
| Mark A Schlossberg | SVP - Legal & General Counsel | 15 Mart 2022 M | 103.408 | 0 | 0 | $0 |
| David Cragg | Chief HR & Admin Officer | 07 Mart 2022 F | 153.233 | 0 | 0 | $0 |
| Caryn Gordon Mcdowell | GC & Chief Compliance Officer | 27 Şubat 2018 A | 32.548 | 0 | 0 | $0 |
| Peter S Roddy | SVP Finance & CAO | 27 Şubat 2018 A | 21.520 | 0 | 0 | $0 |
| Bradley Paul Morgan | SVP Drug Discovery & Early Dev | 31 Ağustos 2017 M | 46.441 | 0 | 0 | $0 |
| Bonnie Charpentier | SVP Regulatory & Compliance | 28 Şubat 2017 A | 29.004 | 0 | 0 | $0 |
| Andrew A Wolff | SVP & CMO | 28 Şubat 2017 A | 47.255 | 0 | 0 | $0 |
| David J Morgans JR | EVP-Preclinical R&D | 28 Şubat 2011 A | 42.000 | 0 | 0 | $0 |
| Michael Rabson | SVP Business Dev/Legal & GC | 18 Aralık 2009 M | 20.043 | 0 | 0 | $0 |
| Jay K Trautman | VP, Discovery Research | 29 Şubat 2008 A | 47.896 | 0 | 0 | $0 |
| Robert Arthur Harrington | Yönetim kurulu üyesi | 15 Temmuz 2026 A | 21.932 | 0 | 2 | $-248.260 |
| James M Daly | Yönetim kurulu üyesi | 15 Temmuz 2026 A | 3.390 | 0 | 0 | $0 |
| Edward M. Kaye MD | Yönetim kurulu üyesi | 15 Temmuz 2026 A | 10.434 | 0 | 6 | $-3.544.372 |
| Nancy Wysenski | Yönetim kurulu üyesi | 15 Temmuz 2026 A | 33.992 | 0 | 0 | $0 |
| Wendell Wierenga | Yönetim kurulu üyesi | 15 Temmuz 2026 A | 35.563 | 0 | 3 | $-1.881.925 |
| John T Henderson | Yönetim kurulu üyesi | 15 Temmuz 2026 A | 78.360 | 0 | 2 | $-2.078.525 |
| Lynne B Parshall | Yönetim kurulu üyesi | 01 Haziran 2026 S | 15.784 | 0 | 3 | $-1.000.100 |
| Muna Bhanji | Yönetim kurulu üyesi | 27 Mayıs 2026 A | 26.361 | 0 | 0 | $0 |
| Robert E Landry | Yönetim kurulu üyesi | 27 Mayıs 2026 A | 10.184 | 0 | 0 | $0 |
| Wendall Wierenga | Yönetim kurulu üyesi | 15 Temmuz 2025 A | 32.345 | 0 | 0 | $0 |
| COSTA SANTO J | Yönetim kurulu üyesi | 15 Mayıs 2024 A | 20.600 | 0 | 0 | $0 |
| Sandford D Smith | Yönetim kurulu üyesi | 02 Ocak 2024 A | 18.801 | 0 | 0 | $0 |
| Robert Califf | Yönetim kurulu üyesi | 03 Ocak 2022 A | 6.003 | 0 | 0 | $0 |
| GAGE L PATRICK | Yönetim kurulu üyesi | 08 Kasım 2021 M | 28.932 | 0 | 0 | $0 |
| Denise Gilbert | Yönetim kurulu üyesi | 20 Mayıs 2015 J | — | 0 | 0 | $0 |
| Stephen M Dow | Yönetim kurulu üyesi | 02 Ocak 2013 A | 1.421.052 | 0 | 0 | $0 |
| James A Spudich | Yönetim kurulu üyesi | 18 Mayıs 2011 A | 180.600 | 0 | 0 | $0 |
| Grant A Heidrich III | Yönetim kurulu üyesi | 03 Ocak 2011 A | 93.755 | 0 | 0 | $0 |
| Michael Schmertzler | Yönetim kurulu üyesi | 03 Haziran 2010 S | 4.340.923 | 0 | 0 | $0 |
| Mark Mcdade | Yönetim kurulu üyesi | 21 Mayıs 2009 A | — | 0 | 0 | $0 |
| Charles J Homcy | Yönetim kurulu üyesi | 22 Mayıs 2008 A | — | 0 | 0 | $0 |
| William J Rutter | Yönetim kurulu üyesi | 29 Nisan 2004 C | 172.413 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VI LP | 10% sahip | 29 Nisan 2004 C | 1.615.716 | 0 | 0 | $0 |
| SRB ASSOCIATES VIII LP | 10% sahip | 29 Nisan 2004 C | 771.052 | 0 | 0 | $0 |
| SRB ASSOCIATES VII LP | 10% sahip | 29 Nisan 2004 C | 650.000 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VIII LP | 10% sahip | 29 Nisan 2004 C | 755.631 | 0 | 0 | $0 |
| Robert I Blum | — | 10 Ağustos 2026 M | 377.820 | 0 | 19 | $-9.702.097 |
| Elisabeth Schnieders | — | 28 Şubat 2017 A | 43.919 | 0 | 0 | $0 |
| James H Sabry | — | 03 Haziran 2010 M | 0 | 0 | 0 | $0 |
| SEVIN ROSEN VII AFFILIATES FUND LP | — | 29 Nisan 2004 C | 24.050 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VII LP | — | 29 Nisan 2004 C | 625.950 | 0 | 0 | $0 |
| SRB ASSOCIATES VI LP | — | 29 Nisan 2004 C | 1.742.951 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 84 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| LFSC · RBB Fund, Inc. | 3,16% | 43.268 NS | 31 Mayıs 2026 | N-PORT |
| HRTS · Tema ETF Trust | 2,52% | 17.069 NS | 31 Mayıs 2026 | N-PORT |
| FMED · Fidelity Covington Trust | 1,55% | 8.262 NS | 31 Mayıs 2026 | N-PORT |
| GDOC · Goldman Sachs ETF Trust | 1,40% | 3.663 NS | 31 Mayıs 2026 | N-PORT |
| JSMD · Janus Detroit Street Trust | 1,24% | 189.801 NS | 30 Nisan 2026 | N-PORT |
| JSML · Janus Detroit Street Trust | 0,98% | 48.338 NS | 30 Nisan 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,94% | 76.297 NS | 30 Nisan 2026 | N-PORT |
| BBC · ETFis Series Trust I | 0,75% | 4.355 NS | 30 Nisan 2026 | N-PORT |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,51% | 41.612 NS | 30 Nisan 2026 | N-PORT |
| BIB · ProShares Trust | 0,47% | 4.553 NS | 31 Mayıs 2026 | N-PORT |
| NUSC · Nushares ETF Trust | 0,47% | 94.565 NS | 30 Nisan 2026 | N-PORT |
| MIDE · DBX ETF Trust | 0,41% | 178 NS | 29 Mayıs 2026 | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0,34% | 16.959 NS | 30 Nisan 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,26% | 55.086 NS | 30 Nisan 2026 | N-PORT |
| ITWO · ProShares Trust | 0,25% | 6.062 NS | 31 Mayıs 2026 | N-PORT |
| RSSL · Global X Funds | 0,23% | 51.834 NS | 30 Nisan 2026 | N-PORT |
| PTMC · Pacer Funds Trust | 0,23% | 14.028 NS | 30 Nisan 2026 | N-PORT |
| MVV · ProShares Trust | 0,22% | 4.565 NS | 31 Mayıs 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,21% | 635.330 NS | 31 Mayıs 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0,20% | 19.862 NS | 30 Nisan 2026 | N-PORT |
| SCHM · SCHWAB STRATEGIC TRUST | 0,19% | 356.940 NS | 31 Mayıs 2026 | N-PORT |
| FFSM · FIDELITY COVINGTON TRUST | 0,19% | 37.821 NS | 30 Nisan 2026 | N-PORT |
| MIDU · Direxion Shares ETF Trust | 0,15% | 2.025 NS | 30 Nisan 2026 | N-PORT |
| UMDD · ProShares Trust | 0,15% | 638 NS | 31 Mayıs 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,15% | 11.444 NS | 30 Nisan 2026 | N-PORT |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,15% | 47.609 NS | 30 Nisan 2026 | N-PORT |
| UWM · ProShares Trust | 0,15% | 4.765 NS | 31 Mayıs 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,15% | 2.868 NS | 30 Nisan 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,12% | 53.720 NS | 30 Nisan 2026 | N-PORT |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,12% | 154 NS | 31 Mayıs 2026 | N-PORT |
| NBCR · Neuberger Berman ETF Trust | 0,10% | 12.090 NS | 31 Mayıs 2026 | N-PORT |
| URTY · ProShares Trust | 0,10% | 4.793 NS | 31 Mayıs 2026 | N-PORT |
| FSCC · Federated Hermes ETF Trust | 0,06% | 2.263 NS | 31 Mayıs 2026 | N-PORT |
| FFLG · FIDELITY COVINGTON TRUST | 0,06% | 5.490 NS | 30 Nisan 2026 | N-PORT |
| ESLV · Strategy Shares | 0,05% | 100 NS | 30 Nisan 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,05% | 4.582 NS | 31 Mayıs 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0,05% | 5.851 NS | 31 Mayıs 2026 | N-PORT |
| HDG · ProShares Trust | 0,04% | 121 NS | 31 Mayıs 2026 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0,02% | 30.621 NS | 31 Mayıs 2026 | N-PORT |
| TILT · FlexShares Trust | 0,02% | 5.462 NS | 30 Nisan 2026 | N-PORT |
| SCHK · SCHWAB STRATEGIC TRUST | 0,01% | 10.669 NS | 31 Mayıs 2026 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0,01% | 78.165 NS | 31 Mayıs 2026 | N-PORT |
| GUSA · Goldman Sachs ETF Trust II | 0,01% | 3.973 NS | 31 Mayıs 2026 | N-PORT |
| AVSU · AMERICAN CENTURY ETF TRUST | 0,01% | 570 NS | 31 Mayıs 2026 | N-PORT |
| AVLC · AMERICAN CENTURY ETF TRUST | 0,01% | 1.547 NS | 31 Mayıs 2026 | N-PORT |
| AVUQ · AMERICAN CENTURY ETF TRUST | 0,01% | 173 NS | 31 Mayıs 2026 | N-PORT |
| FTLS · First Trust Exchange-Traded Fund III | -0,10% | -35.935 NS | 30 Nisan 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | — | — | 15 Temmuz 2026 | Günlük |
| VB · VANGUARD INDEX FUNDS | — | — | 15 Temmuz 2026 | Günlük |
| VBK · VANGUARD INDEX FUNDS | — | — | 15 Temmuz 2026 | Günlük |